Abigail Brooks, MA

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.

Iyer reviews findings from subgroup analyses of the phase 3 STARS study of apraglutide for SBS-IF based on demographics and disease characteristics.

Dellon reviews phase 3 data supporting the 48-week safety and efficacy of cendakimab for treating EoE.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.

Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.

Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.

Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.

Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.

Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.

Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.

HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.

Patients with greater HADS-D scores were less likely to achieve symptomatic response or remission with a 2-step dietary intervention for IBS.